15results about How to "Lower triglyceride levels" patented technology

The invention discloses application of caffeic acid phenethyl ester to improvement of negative effects of high-carbohydrate feed on fish growth and metabolism, and belongs to the technical field of aquaculture. The caffeic acid phenethyl ester is added into a high-carbohydrate feed formula, so that the metabolic capability of adipose tissues, livers and muscles of the grass carp and the weever on glucose can be remarkably enhanced, ectopic deposition of lipid in the livers and the muscles is relieved, fatty liver diseases are improved, muscle protein deposition is promoted, and the immunity of the grass carp and the weever is improved. The inhibiting effect of the high-carbohydrate feed on the growth performance of the grass carp and the weever is reversed. The invention further provides formulas of the high-carbohydrate feed containing the caffeic acid phenethyl ester for the grass carp and the weever respectively, and data support is provided for research on improvement of the utilization capacity of the grass carp and the weever on the high-carbohydrate feed.

The invention belongs to the field of pharmaceutical preparations. The invention relates to lipid nanoparticles modified by probiotic coupled galactose and coated with diammonium glycyrrhizinate, L-arginine and copper tannic acid nano enzyme as well as a preparation method and application of the lipid nanoparticles. The lipid nanoparticles prepared by coupling and wrapping the diammonium glycyrrhizinate, the L-arginine and the copper tannic acid nano-enzyme with the probiotics have good biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, the half-life period of a medicine circulating in a body can be prolonged, the inherent beneficial functions of the probiotics are cooperated, and the bioavailability of the medicine is improved. The potential application value is realized in the fields of treating the metabolic dysfunction related steatohepatitis and the like.

This invention discloses a strain of *Lactobacillus plantarum* CCFM1487 and its prepared metagener for lowering lipids and alleviating fatty liver, as well as its application in converting cassiaside. It belongs to the fields of microbial technology and food and health product technology. This strain can efficiently convert cassiaside into cassiaside aglycone. The core of this invention lies in providing a metagener prepared from this strain through fermentation and inactivation treatment. Experiments in a high-fat diet mouse model have demonstrated that it significantly reduces serum total cholesterol and triglyceride levels, and can alleviate hepatic lipid deposition and improve hepatic steatosis. Based on this metagener, foods, medicines, or health products can be developed for the prevention and / or adjuvant treatment of metabolic disorders such as hyperlipidemia and non-alcoholic fatty liver disease, possessing significant application value.

The invention discloses a tea substitute drink for preventing and treating hyperuricemia. The tea substitute drink comprises the following raw materials: codonopsis pilosula, bighead atractylodes rhizome, rhizoma atractylodis, poria cocos, rhizoma smilacis glabrae, honeysuckle, edible tulip, salvia miltiorrhiza, gynostemma pentaphylla and the like. The traditional Chinese medicine composition has the effects of replenishing qi to invigorate the spleen, clearing damp and reducing phlegm, clearing away heat and toxic materials, removing blood stasis and promoting coronary circulation, effectively prevents and treats hyperuricemia, and reduces hyperuricemia complicated with cardiovascular and cerebrovascular diseases. The blood uric acid and triglyceride levels of patients can be effectively reduced, the blood fat can be reduced, and the morbidity of hyperuricemia accompanied by cardiovascular and cerebrovascular diseases can be reduced. The traditional Chinese medicine composition is prepared from various Chinese herbal medicine raw materials, has small side effects on a human body, is low in preparation cost and can be widely applied to treatment of hyperuricemia.

The invention belongs to the technical field of microbial fermentation, and particularly relates to a corn steep liquor leavening containing free inositol and application thereof.A microbial fermentation method is adopted, corn steep liquor and aspergillus niger leavening are mixed and subjected to enzymolysis, then the mixture is mixed with aspergillus oryzae leavening, lactobacillus acidophilus and bacillus pumilus are inoculated, and the free inositol-containing corn steep liquor leavening is obtained through fermentation. The content of free inositol is not lower than 1.15%, so that the nutritional value of the corn steep liquor is effectively improved; when the obtained corn steep liquor fermentation product is applied to animal feed, the daily gain can be increased and the feed-gain ratio can be reduced in the aspect of the growth performance of meat rabbits; in the aspect of serum biochemical indexes, the content of total protein, albumin, total cholesterol, low-density lipoprotein, high-density lipoprotein, blood calcium and serum phosphorus can be increased, and the content of urea nitrogen and triglyceride can be reduced; and in the aspect of slaughter performance, the carcass weight, the semi-eviscerated slaughter rate and the full-eviscerated slaughter rate can be improved.

The invention belongs to the technical field of microorganisms and metagens, and discloses a pediococcus acidilactici LTJ51 with lipid-lowering and weight-losing capacity, a metagen of the pediococcus acidilactici LTJ51 and application of the pediococcus acidilactici LTJ51, the name of the pediococcus acidilactici LTJ51 is LTJ51, the classification name of the pediococcus acidilactici LTJ51 is pediococcus acidilactici, the preservation number of the pediococcus acidilactici LTJ51 is CGMCC No.31545, the preservation date of the pediococcus acidilactici LTJ51 is August 5, 2024, and the preservation number of the pediococcus acidilactici LTJ51 is CGMCC No.31545. The strain is preserved in China General Microbiological Culture Collection Center (CGMCC), No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici disclosed by the invention is derived from fermented grains in the fermentation process of traditional fermented food white spirit, belongs to a strain pediococcus acidilactici LTJ51 which is recognized to be safe and can be used for food, and is safe in source and free of pathogenicity. The pediococcus acidilactici has the effect of relieving, improving or treating the HFD-induced obesity.

This invention relates to a 9-(p-chlorocinnamoylamino)berberine derivative as shown in Formula I, the structure of which is an amide compound formed by demethoxylation and amination at the 9-position of the berberine nucleus followed by p-chlorocinnamoyl group. The invention also provides a method for preparing this compound, comprising demethoxylating berberine at the 9-position to convert it into a 9-aminoberberine intermediate, followed by an acylation reaction with p-chlorocinnamoyl chloride. Pharmacological studies have shown that the compound has significant lipid-lowering and hypoglycemic effects and can be used to prepare drugs for the prevention or treatment of hyperlipidemia, diabetes, and related metabolic syndromes.

The invention discloses an application of amentoflavone in preparation of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor. In an enzyme activity test, amentoflavone has a very remarkable inhibition effect on ACLY, and the median inhibitory concentration (IC50) is 0.25 + / -0.06 mu M; animal experiments show that amentoflavone can reduce the body weight, blood sugar, liver weight, fat weight, triglyceride and the like of non-alcoholic fatty liver disease mice which are molded by high-fat, high-cholesterol and high-fructose feed diet. Therefore, the amentoflavone has a potential treatment value on ACLY related diseases, such as the non-alcoholic fatty liver disease.

According to the invention, a virtual screening method based on molecular docking is adopted to obtain 14 Miao compounds with relatively strong binding capacity with a farnesol X receptor. A series of in-vitro experiments are carried out on 14 Miao compounds, including a farnesol X receptor agonistic activity experiment, detection of the cytotoxicity of the compounds by an MTT method, and testing of the influence of the compounds on the triglyceride level of free fatty acid induced HepG2 cells by a GPO-PAP method. Experimental results show that the 14 compounds all have obvious agonistic activity on farnesoid X receptors, and have no cytotoxicity on HepG2 cells and L02 cells. Particularly, the compound 1, the compound 2 and the compound 3 can obviously reduce the content of triglyceride in HepG2 cells with fatty degeneration. Experimental results show that the 14 compounds can be further developed into drugs for treating farnesoid X receptor mediated diseases such as non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis, cholestatic liver diseases, hepatic fibrosis and the like.

The present invention relates to the technical field of probiotic application, and in particular to a Lactobacillus plantarum LP4 capsule polysaccharide extract and its application. The preparation method of the Lactobacillus plantarum LP4 capsule polysaccharide extract comprises: taking Lactobacillus plantarum ( Lactobacillus plantarum ) LP4 was fermented and cultured, the fermentation liquid was centrifuged, the bacteria were collected, and hot water extraction was performed. The extract was centrifuged, the supernatant was collected, and crude polysaccharides were obtained by ethanol precipitation; after deproteinization with trichloroacetic acid, dialyzation was performed using a 7000Da dialysis bag, and the retained material was vacuum freeze-dried to obtain the Lactobacillus plantarum LP4 capsular polysaccharide extract. The Lactobacillus plantarum LP4 capsular polysaccharide extract can significantly reduce the triglyceride and total cholesterol content in the serum and liver of obese mice, and alleviate the liver amino acid metabolism disorder caused by a high-fat diet, and effectively reduce liver damage caused by a high-fat diet.

The invention relates to application of insulin-like growth factor binding protein-1 in preparation of drugs for treating non-alcoholic fatty liver diseases, and belongs to the technical field of biological medicines. The invention discloses the new application of the insulin-like growth factor binding protein-1 in preparing the medicine for treating the non-alcoholic fatty liver disease for the first time, effectively proves that the insulin-like growth factor binding protein-1 can effectively reverse liver lipid accumulation caused by Dox, MCDD and HFD, remarkably improves liver injury caused by Dox, MCDD and HFD, and has the advantages that the medicine can be used for treating the non-alcoholic fatty liver disease; the content of triglyceride in the liver and the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in blood are reduced, so that the effect of preventing or treating the non-alcoholic fatty liver disease is achieved. Therefore, the insulin-like growth factor binding protein-1 can be used for preparing the medicine for treating the non-alcoholic fatty liver disease, and has important significance in clinical treatment of the non-alcoholic fatty liver disease in the future.

The application provides use of a specific KPNA2 agonist and a combination of the specific KPNA2 agonist and other substances in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific KPNA2 agonist can significantly reduce liver triglyceride levels, thereby reducing alcohol-induced liver steatosis, and has good clinical conversion prospects, and the combination of the specific KPNA2 agonist and other substances has better effects.

The invention discloses a fat-reducing composition containing plant extract ingredients and a preparation method thereof, and belongs to the technical field of fat-reducing compositions. The method comprises the following steps: mixing starch, disodium hydrogen phosphate, citric acid, and deionized water, adding α-amylase, adjusting pH, centrifuging, and treating the solid phase to obtain material A; mixing material A, sodium alginate, Dendrobium officinale extract, and deionized water to obtain material B; mixing pig liver powder, cuttlebone powder, gluconolactone, sucrose fatty acid ester, and deionized water, adding material B, heating to 85-95°C, adding plant extracts, homogenizing, and spray drying to obtain a fat-reducing composition containing plant extract ingredients with good lipid-lowering effect.

The invention provides an application of calcium beta-hydroxy-beta-methylbutyrate in improving the production performance of horses, and belongs to the technical field of animal breeding. Research finds that the milk yield of mare can be remarkably increased through supplementary feeding of the calcium beta-hydroxy-beta-methylbutyrate, but milk components are not remarkably influenced; the content of urea in plasma can be reduced on the 30th day after the calcium beta-hydroxy-beta-methylbutyrate is fed, and the content of blood sugar, the content of total bilirubin and the content of triglyceride can be remarkably reduced on the 60th day, and the content of total protein can be increased. And the calcium beta-hydroxy-beta-methylbutyrate can effectively improve the production performance of the mare.

The invention belongs to the technical field of wine brewing, and discloses cordyceps militaris and highland barley beer with a health-care function and a preparation method thereof, the preparation method comprises the following steps: S1, concentrating cordyceps militaris fermentation filtrate under reduced pressure, filtering, and drying to obtain cordyceps militaris polysaccharide for later use; s2, taking a mixture of wheat malt and highland barley malt as a raw material, saccharifying, filtering to obtain wort, boiling the wort, and adding hops in the boiling process; s3, standing the boiled wort, cooling to 18 DEG C, inoculating the wort with fermentation yeast paste, stopping fermentation when the residual sugar of the fermentation liquor is reduced to 1.2 DEG P, and storing to obtain the beer for later use; and S4, adding the prepared cordyceps polysaccharide into the beer to obtain the cordyceps highland barley beer with the health-care function. The cordyceps militaris and highland barley beer has the effects of enhancing immunity, resisting oxidation and aging, regulating blood sugar, promoting digestion and improving cardiovascular health.